Session Information
Session Type: ACR Poster Session A
Session Time: 9:00AM-11:00AM
Background/Purpose: Targeting humoral immunity has been proved effective in several inflammatory rheumatic diseases (IRD). Though clinical trials have shown some efficacy of B-cell depletion in ankylosing spondylitis (AS), results are less convincing. Other studies have revealed an association between mutations and expression of immune regulatory genes suggesting a B-cell dysfunction in the development and progression of AS. Yet, there is still lack of data describing B-cell subsets in AS. The study purpose is to assess and compare the immature, naive and antigen differentiated subsets of peripheral B-cell compartment in AS with those in healthy controls (HC) and other IRD
Methods: Patients with AS, RA and SLE according to respective classification criteria were included. Patients under biologic DMARDS were not included. Sociodemographic and clinical variables were recorded and blood samples were collected for quantification of inflammatory markers, immunoglobulin levels and assessment of B-cell immature transitional stages and mature subsets by flow cytometry. Mann-Whitney and Fisher´s exact test were used for statistical analysis
Results: Overall, 60 patients and 12 HC were included. All patient groups presented similar and rather low levels of inflammation, as measured by CRP, ESR and immunoglobulins, in addition to a decreased lymphocyte count. There were no differences in the B-cell counts between AS patients and HC, and both groups had higher B-cell counts than RA and SLE patients. Regarding B-cell subsets, the immature transitional compartment of AS patients was found in normal range, but not in RA and SLE. The latter presented a significant decrease in all transitional cell maturity stages (T1-T3). The next step in B-cell differentiation is mature naïve cells, also found to be normal in AS and decreased in RA and SLE. AS patients presented slightly higher counts of CD27+IgD+ MZ-like and class able to switch memory cells with reference to HC and these cell numbers were found to be low in RA and SLE patients. Switched memory CD27+IgD- B-cells were reduced in all patient groups, however, only SLE patients presented highly decreased cell levels
Conclusion: We found that while a severe dysfunction is present in the homeostasis of the B-cell compartment in RA and in particular SLE pts, which are lymphopenic in both immature and mature B-cell compartments, it appears that AS patients are not affected in the same way. At this stage, functional studies appear to be necessary in order to identify differences in key mechanisms of B cell development and differentiation that play a role in the aetiology and progression of these inflammatory rheumatic diseases. Our first results, however, establish that pathophysiological mechanisms involving B-cells clearly differentiate AS from RA and SLE
AS (n=22) |
RA (n=20) |
SLE (n=18) |
HC (n=12) |
|||
Male, Female; n (%) |
11 (50); 11 (50) |
9 (45); 11 (55) |
5 (27.8); 13 (72.2) |
3 (25); 9 (75) |
||
Age; median (IQR) |
56 (45.8-65.5) |
55 (51-65.5) |
44 (37.5-52.5)* |
56 (35.3-63.3) |
||
ESR mm/hour |
14 (10-29.3) |
21 (10.3-37.8) |
23 (6-34.5) |
11 (8-22.5) |
||
CRP mg/dL |
1.1 (0.9-1.7) |
0.98 (0.7-3.2) |
0.6 (0.5-1.6) |
– |
||
HLA B27+: n (%) |
11 (68.8) |
– |
– |
– |
||
With csDMARS, n (%) |
6 (30) |
18 (90) |
15 (83.3) |
0 |
||
Ig seric levels, mg/dl; median (IQR) |
||||||
IgG |
1165 (881.3-1247.5) |
1021 (830.3-1265) |
1140 (1003-1325 |
1033.5 (823.3-1235) |
||
IgA |
230 (158.8-340) |
250.5 (164.3-315.3) |
261 (205-323) |
236.5 (150.3-339.8) |
||
IgM |
95.3 (65.6-119.5) |
112 (67.7-164.8) |
103 (60.6-131.5 |
122 (71.5-158.3) |
||
Absolute cell counts/μl blood; median (IQR) |
||||||
Lymphocytes |
1685 (1217-2007.5) |
1555 (1097.5-2085) |
1250 (625-1892.5) |
2170 (1830-2377)** |
||
Total B-cells (CD20+) |
186.3(111-238.6) |
96.2 (50.3-180.6)*** |
65.8 (20.9-116.1)*** |
182.1 (100.9-269.7) |
||
Immature Transitional B-cells (CD5+CD27–IgD+), median (IQR) |
||||||
CD24+++CD38+++(T1) |
2.8 (1.8-3.9) |
0.6 (0.1-2.7)** |
1.5 (0.2-2.8)** |
4.3 (2.3-6.5) |
||
CD24++CD38++(T2) |
8.3 (5.1-14.9) |
2.6 (0.2-8.0)** |
3.0 (1.0-8.0)** |
13.7 (5.7-18.8) |
||
CD24+CD38+(T3) |
9.0 (5.5-17.7) |
2.2 (0.3-4.6)** |
1.9 (0.2-3.7)** |
7.7 (4.1-12.3) |
||
Mature B-Cells, median (IQR) |
||||||
CD27–IgD+ (naïve) |
73.2 (49.7-121.7) |
40.1(19.2-76.9)** |
27.2(11.9-57.1) † |
78.6 (48.4-163.4) |
||
CD27+IgD+(mem. MZ-like) |
25.9 (13.6-39.9) |
13.0 (3.5-27.2)** |
2.6 (1.8-9.6) † |
18.9 (11.2-27.1) |
||
CD27+IgD–(switch mem.) |
18.8 (12.2-37.9) |
13.5 (3.9-37.6) |
4.9 (2.2-17.2)*** |
29.3 (14.51-37.9) |
||
CD27–IgD–(double neg.) |
2.4 (1.8-5.2) |
3.1 (2.0-6.4) |
2.9 (1.0-5.0) |
5.2 (2.6-8.1) |
||
Mann-Whitney and the Fisher´s exact test were used for comparison between AS and other groups
* p<0.05; **p<0.02; ***p<0.01; †p<0.0001;
To cite this abstract in AMA style:
Lagoas Gomes J, Ligeiro D, Lima A, Teixeira C, Sepriano A, Ramiro S, Lopes C, Costa T, Costa M, Branco JC, Pimentel-Santos F. B-Cell Subset Differences in Inflammatory Rheumatic Diseases [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/b-cell-subset-differences-in-inflammatory-rheumatic-diseases/. Accessed .« Back to 2017 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/b-cell-subset-differences-in-inflammatory-rheumatic-diseases/